Dimethyl Sulfoxide
Apexbio Technology LLC Rosiglitazone(Synonyms: Avandia, BRL-49653, Rosiglitazone Maleate, Rosiglitazone Base, BRL49653C, RGZ, Rosiglizole), 10mM (in 1mL DMSO), CAS: 122320-73-4.
Rosiglitazone (CAS 122320-73-4) is a synthetic thiazolidinedione (TZD) that functions as an agonist of peroxisome proliferator-activated receptor gamma (PPAR ) a nuclear receptor highly expressed in adipose tissues Upon ligand binding PPAR forms heterodimers with retinoid X receptors promoting transcriptional activation of genes regulating adipogenesis glucose uptake lipid metabolism and insulin sensitivity Through modulating fatty acid storage in adipose tissue and secretion of adipokines rosiglitazone significantly enhances insulin sensitivity making it extensively utilized in metabolic and diabetes research particularly type II diabetes studies
Apexbio Technology LLC R406 (free base) 841290-80-0 10mM (in 1mL DMSO)
R406 (free base CAS 841290-80-0) is a small molecule inhibitor of spleen tyrosine kinase (SYK) a non-receptor kinase expressed predominantly within hematopoietic cells As an ATP-competitive inhibitor R406 selectively binds SYK s ATP-binding domain thereby suppressing its kinase activity and downstream phosphorylation events (IC50 41 nM) In mast cells R406 inhibits Fc receptor-driven degranulation with an EC50 value of 56-64 nM In diffuse large B-cell lymphoma models it blocks SYK-dependent B-cell receptor signaling through impaired autophosphorylation at sites Y525/Y526 resulting in apoptosis This compound is orally bioavailable and serves as a research tool for hematologic malignancies and autoimmune diseases
Apexbio Technology LLC Rucaparib (free base) 283173-50-2 10mM (in 1mL DMSO)
Rucaparib (free base) (CAS 283173-50-2) also known as AG014699 or PF-01367338 is a pharmacological inhibitor targeting poly(ADP-ribose) polymerase (PARP) a nuclear enzyme centrally involved in DNA damage signaling and base excision repair pathways By impeding PARP activity Rucaparib compromises DNA repair capacity leading to persistent DNA strand breaks as evidenced by increased gamma-H2AX and p53BP1 foci It has demonstrated radiosensitizing properties in prostate cancer cells notably those harboring PTEN deficiency or expressing ETS gene fusion proteins due partly to inhibition of non-homologous end-joining (NHEJ) DNA repair Rucaparib serves as a tool compound in oncology research to study chemosensitization and radiosensitization strategies
Apexbio Technology LLC CCT128930 HCl 885499-61-6 (free base) 10mM (in 1mL DMSO)
CCT128930 HCl is a potent selective ATP-competitive inhibitor targeting AKT2 kinase with an IC50 of approximately 6 nM It exhibits higher selectivity for AKT2 compared to related kinases such as PKA and p70S6K Akt protein kinase involved in diverse cellular pathways including metabolism proliferation apoptosis transcription control and cell mobility is frequently deregulated in various tumor types In cancer cell models CCT128930 HCl impairs cellular proliferation and reduces phosphorylation of specific Akt downstream substrates Preclinical studies employing PTEN-deficient glioma cells and breast cancer xenograft models show inhibition of signaling activity and tumor growth Consequently CCT128930 HCl serves as a promising research tool for studying Akt-mediated signaling mechanisms pathway regulation and potential therapeutic responses in cancer biology
Apexbio Technology LLC SGI-1776 free base 1025065-69-3 10mM (in 1mL DMSO)
SGI-1776 free base (CAS 1025065-69-3) is an ATP-competitive inhibitor targeting Pim kinases a serine/threonine protein kinase family implicated in regulating cellular survival pathways It selectively inhibits all three isoforms Pim-1 Pim-2 and Pim-3 leading to decreased phosphorylation of downstream substrates involved in cell cycle regulation and apoptosis such as p21Cip1/WAF1 and Bad Cellular studies indicate that SGI-1776 induces G1 cell cycle arrest promotes apoptosis and overcomes chemoresistance mediated by multidrug resistance protein 1 (MDR1) in taxane-resistant prostate cancer cells
Apexbio Technology LLC SCH772984 HCl 942183-80-4 (free base) 10mM (in 1mL DMSO)
SCH772984 HCl is a selective inhibitor targeting extracellular signal-regulated kinases 1 and 2 (ERK1/2) members of the mitogen-activated protein kinase (MAPK) pathway ERK activation is commonly implicated in cancer proliferation particularly in tumors harboring BRAF or RAS mutations SCH772984 HCl binds specifically to ERK1/2 blocking their kinase activity and downstream substrate phosphorylation In cell-based experiments it inhibits phosphorylation of ERK substrates such as p90 ribosomal S6 kinase (RSK) and decreases phosphorylation of ERK1/2 activation-loop residues In vivo SCH772984 HCl reduces tumor growth in xenograft mouse models bearing human melanoma cells with BRAF V600E mutation This compound is widely used in cancer research to study ERK-mediated signaling pathways and models exhibiting resistance to BRAF and MEK inhibitor therapies
Apexbio Technology LLC LY2157299(Synonyms: Galunisertib, LY-2157299, LY2157299 monohydrate, LY2157299 hydrate, LY2157299 free base), 10mM (in 1mL DMSO), CAS: 700874-72-2.
LY2157299 (CAS 700874-72-2) is a small-molecule antagonist that selectively targets the transforming growth factor-beta type I receptor (T RI) By blocking signaling through T RI it prevents phosphorylation of downstream effectors Smad2 and Smad3 thereby interfering with the TGF- signaling pathway Preclinical studies indicate LY2157299 inhibits 1-integrin activation reduces tumor cell invasion lowers connective tissue growth factor (CTGF) production and suppresses angiogenesis Currently in phase II clinical trials LY2157299 is being investigated primarily for therapeutic potential against hepatocellular carcinoma and glioblastoma
Medchemexpress LLC Docosahexnc Acid 10Mm-1Ml Dmso | HY-B2167-10MM-1ML DMSO
Docosahexnc Acid 10Mm-1Ml Dmso
Medchemexpress LLC Arachidonic Acid-10Mm-1Ml Dmso | HY-109590-10MM-1ML DMSO
Arachidonic Acid-10Mm-1Ml Dmso
Apexbio Technology LLC Sotrastaurin (AEB071)(Synonyms: AEB071, Sotrastaurin, PKC inhibitor AEB071, PKC inhibitor Sotrastaurin, Sotrastaurin base, AEB-071), 10mM (in 1mL DMSO), CAS: 425637-18-9.
Sotrastaurin (AEB071 CAS 425637-18-9) is a small-molecule inhibitor targeting protein kinase C (PKC) with inhibitory activity against classical and novel PKC isoforms PKC plays an integral role in immune cell signaling influencing T-cell activation proliferation and cytokine synthesis Sotrastaurin blocks PKC-mediated pathways thereby suppressing T-cell activation proliferation IL-2 mRNA expression and NK-cell function as demonstrated in ex vivo lymphocyte assays Due to its immunoregulatory properties Sotrastaurin has potential therapeutic applications in autoimmune conditions including psoriasis
Apexbio Technology LLC (S)-(+)-Ibuprofen(Synonyms: Dexibuprofen, (S)-Ibuprofen, (S)-(+)-2-(4-Isobutylphenyl)propionic acid), 10mM (in 1mL DMSO), CAS: 51146-56-6.
(S)-( )-Ibuprofen (CAS 51146-56-6) is the pharmacologically active enantiomer of the racemic nonsteroidal anti-inflammatory drug (NSAID) ibuprofen Unlike its R(-)-counterpart the S( )-form selectively inhibits cyclooxygenase (COX) enzymes thereby suppressing prostaglandin synthesis at concentrations relevant to clinical settings Due to this stereoselectivity (S)-( )-ibuprofen is widely utilized in biomedical research investigating pain inflammation pathways COX enzyme activity and related drug-target interactions
Apexbio Technology LLC Alendronate sodium(Synonyms: Alendronate sodium hydrate, Sodium alendronate, Alendronic acid monosodium salt, Fosamax), 10mM (in 1mL DMSO), CAS: 129318-43-0.
Alendronate sodium (CAS 129318-43-0) is a small molecule inhibitor of osteoclast-driven bone resorption It acts by selectively inhibiting farnesyl diphosphate synthase (FPPS) an essential enzyme within the mevalonate (HMG-CoA reductase) pathway exhibiting an IC50 of approximately 460 nM against recombinant human FPPS Inhibition of FPPS prevents protein prenylation and sterol biosynthesis within osteoclasts subsequently inducing apoptosis in macrophage-lineage cells Alendronate sodium is commonly utilized in biomedical research focused on bone metabolism disorders osteoclast biology and evaluation of therapeutic strategies targeting bone density loss
Apexbio Technology LLC URB597(Synonyms: URB-597, KDS-4103, FAAH inhibitor URB597, Cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester), 10mM (in 1mL DMSO), CAS: 546141-08-6.
URB597 (CAS 546141-08-6) also known as KDS-4103 is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH) an enzyme responsible for intracellular hydrolysis of the endocannabinoid anandamide In vitro assays indicate that URB597 inhibits FAAH activity with IC values of 3 nM in human liver microsomes and 52 nM in rat brain membranes Intraperitoneal administration in rats results in FAAH inhibition within brain tissue (ID 0 15 mg/kg) URB597 exhibits minimal interaction with cannabinoid receptors anandamide transporters or other related receptors ion channels enzymes and transporters This selectivity makes URB597 valuable for investigating endocannabinoid signaling pathways in biomedical research
![Apexbio Technology LLC Scriptaid(Synonyms: Scriptaid, HDAC inhibitor Scriptaid, 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide), 10mM (in 1mL DMSO), CAS: 287383-59-9.](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000060690.PNG-250.jpg)
Apexbio Technology LLC Scriptaid(Synonyms: Scriptaid, HDAC inhibitor Scriptaid, 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide), 10mM (in 1mL DMSO), CAS: 287383-59-9.
Scriptaid (CAS 287383-59-9) is a small-molecule histone deacetylase (HDAC) inhibitor originally identified through high-throughput transcriptional screening It specifically targets class I HDAC isoforms inhibiting HDAC1/HDAC3 and HDAC8 with IC50 values of approximately 0 6 M and 1 M respectively Structurally related to other hydroxamic acid-containing HDAC inhibitors such as TSA Scriptaid consists of a hydroxamic acid moiety a connecting linker and an aromatic cap group In glioblastoma (GBM) research Scriptaid shows promise by inducing apoptosis in glioma cells highlighting its potential utility for oncology-focused investigations